Permanent link to this recordhttp://hdl.handle.net/10754/679205
MetadataShow full item record
AbstractThe Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
CitationIbrahim, M. N., & Elfiky, A. A. (2021). Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug. American Journal of Biochemistry and Biotechnology, 17(2), 205–207. doi:10.3844/ajbbsp.2021.205.207
SponsorsComputational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged.